Global safety in adalimumab (HUMIRA®) rheumatoid arthritis clinical trials.

被引：0
|
作者：
Schiff, MH
Burmester, GR
Pangan, AL
Kupper, H
Spencer-Green, GT
机构：
[1] Denver Arthrit Clin PC, Denver, CO USA
[2] Univ Klinikum, Charite, Berlin, Germany
[3] Abbott Labs, Abbott Pk, IL 60064 USA
[4] Abbott Labs, Ludwigshafen, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S562 / S562
页数：1
相关论文
共 50 条
  • [21] THE ARMADA TRIAL: EFFICACY AND SAFETY OF ADALIMUMAB (HUMIRA®) OVER 30 MONTHS IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS
    Weinblatt, M. E.
    Keystone, E. C.
    Furst, D. E.
    Kavanaugh, A.
    Segurado, O. G.
    Spencer-Green, G.
    Chartash, E. K.
    RHEUMATOLOGY, 2004, 43 : 10 - 10
  • [22] RELATIONSHIP OF ADALIMUMAB (HUMIRA™) PHARMACOKINETICS (PK) TO PHARMACODYNAMIC (PD) IN RHEUMATOID ARTHRITIS (RA) PATIENTS DURING PHASE II/III CLINICAL TRIALS
    Granneman, R.
    Zhang, Y.
    Noertersheuser, P.
    Velagapudi, R.
    Awni, W.
    Locke, C.
    Segurado, O.
    Toward, T.
    RHEUMATOLOGY, 2004, 43 : 38 - 38
  • [23] Infliximab failures in rheumatoid arthritis can be successfully treated with adalimumab (Humira®)
    Van der Bijl, AE
    Breedveld, FC
    Antoni, C
    Kalden, JR
    Kary, S
    Burmester, GR
    Voss, B
    Kupper, H
    ANNALS OF THE RHEUMATIC DISEASES, 2004, 63 : 264 - 264
  • [24] Remission and major clinical response in active rheumatoid arthritis (RA) patients after adalimumab (Humira®) treatment
    Burmester, G. M.
    Wordsworth, P.
    McKenna, F.
    Farraccioli, G. F.
    Flipo, R. -M.
    Kary, S.
    Kupper, H.
    RHEUMATOLOGY, 2007, 46 : I28 - I29
  • [25] Factors affecting response to treatment in rheumatoid arthritis (RA) clinical trials.
    Anderson, JJ
    Wells, G
    Verhoeven, AC
    Felson, DT
    ARTHRITIS AND RHEUMATISM, 1998, 41 (09): : S344 - S344
  • [26] Remission and major clinical response in patients with active rheumatoid arthritis (RA) after treatment with adalimumab (Humira®).
    Burmester, G. M.
    Ferraccioli, G. F.
    Flipo, R-M
    Kary, S.
    Kupper, H.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S377 - S377
  • [27] The cost-utility of adalimumab (Humira) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Pang, F.
    Winding, B.
    VALUE IN HEALTH, 2006, 9 (06) : A223 - A223
  • [28] THE COST-EFFECTIVENESS OF ADALIMUMAB (HUMIRA™) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A UK ANALYSIS
    Bansback, N.
    Brennan, A.
    Sengupta, N.
    Pang, F.
    RHEUMATOLOGY, 2004, 43 : 77 - 77
  • [29] The cost-effectiveness of adalimumab (HUMIRA®) in patients with rheumatoid arthritis (RA) in Denmark
    Aagren, M.
    Davies, A.
    Winding, B.
    Cifaldi, M.
    Pang, F.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2006, 35 : 15 - 15
  • [30] Global safety of adalimumab in Crohn's disease clinical trials
    Colombel, Jean-Frederic
    Panaccione, Remo
    Sandborn, William J.
    Rutgeerts, Paul
    Hanauer, Stephen B.
    Reinisch, Walter
    Pollack, Paul F.
    Kent, Jeffrey D.
    Cardoso, Alexandra T.
    Lau, Winne
    GASTROENTEROLOGY, 2008, 134 (04) : A492 - A492
12345